SCHEMBL6870621

SCHEMBL6870621

O=S(=O)(O)c1ccccc1/N=N/c1ccccc1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.61
▸ KMT2A Q03164 2/20 0.61
▸ KDM4E B2RXH2 1/20 0.61
▸ NPC1 O15118 1/20 0.61
▸ LMNA P02545 1/20 0.61
▸ MAPT P10636 1/20 0.61
▸ HTT P42858 1/20 0.61
▸ SMN1; SMN2 Q16637 1/20 0.61
▸ CYP1A2 P05177 3/20 0.47
▸ NSD2 O96028 3/20 0.47
▸ MMP14 P50281 2/20 0.47
▸ CASP6 P55212 2/20 0.47
▸ MPL P40238 4/20 0.44
▸ POLB P06746 1/20 0.44
▸ IDE P14735 1/20 0.44
▸ DUSP3 P51452 1/20 0.44
▸ CCR6 P51684 1/20 0.44
▸ BLM P54132 1/20 0.44
▸ CTRB1 P17538 1/20 0.43
▸ ATIC P31939 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6870626 1.00 MEN1 (0.61) MEN1KMT2AKDM4ENPC1LMNA
SCHEMBL3790419 0.90 CYP1A2 (0.50) MEN1KMT2AKDM4ENPC1LMNA
SCHEMBL31661136 0.81 CYP1A2 (0.60) MEN1KMT2ALMNACYP1A2NSD2
SCHEMBL408152 0.81 POLB (0.58) MEN1KMT2ANPC1MAPTCYP1A2
SCHEMBL31158053 0.81 POLB (0.58) MEN1KMT2ANPC1MAPTCYP1A2
SCHEMBL408151 0.81 POLB (0.58) MEN1KMT2ANPC1MAPTCYP1A2
SCHEMBL11144896 0.80 IDE (0.54) MEN1KMT2ANPC1MAPTCYP1A2
SCHEMBL11144901 0.80 IDE (0.54) MEN1KMT2ANPC1MAPTCYP1A2
SCHEMBL7205854 0.80 SUMO2 (0.43) MEN1KMT2AMAPTSMN1; SMN2CYP1A2
SCHEMBL8744500 0.80 SUMO2 (0.43) MEN1KMT2AMAPTSMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6808616-B2 LOW TEMPERATURE, DIRECT ELECTROCHEMICAL REDUCTION OF A SULFOPHENYLAZOPHENOL DERIVATIVE WITH CARBON ELECTRODE NOVEON IP HOLDINGS CORP. 2004-10-26 — — US disclosed
US-20030098243-A1 Process for the preparation of 5-aminosalicyclic acid NOVEON, INC. 2003-05-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030098243-A1 Process for the preparation of 5-aminosalicyclic acid PGA5, AASDHPPT, TPMT MEN1 4714/4885KMT2A 3349/4885KDM4E 1316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback